Five Biologic Blockbusters Opened Up To EU Biosimilar Competition In 2017

A total of 16 biosimilar products were approved in 2017, including the first competitors to five biologic blockbusters. Coincidentally, 16 other biosimilars are also under evaluation by the European Medicines Agency’s main scientific committee, the CHMP, including six versions of Amgen’s Neulasta (pegfilgrastim) and five more biosimilars of AbbVie’s Humira.